About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
SOHO Highlights: State of the Art and Next Questions
2023
2022
2021
Event
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
MM State of the Art: Approaches to Smoldering, MRD as a Prognostic Marker, Carfilzomib Frontline, Clonal Evolution, IO
By
SOHO Highlights: State of the Art and Next Questions
FEATURING
Sagar Lonial
By
SOHO Highlights: State of the Art and Next Questions
FEATURING
Sagar Lonial
26 views
February 9, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
2021
14:40
SOHO Highlights: State of the Art and Next Questions
Newly Diagnosed ALCL/PTCL State of the Art: How Can We Improve Outco…
Feat.
K. Savage
13:36
SOHO Highlights: State of the Art and Next Questions
SOHO Updates on 1L FL: Does RT+/-(R)CVP Improve PFS in Limited Stage…
Feat.
R. Marcus
14:42
SOHO Highlights: State of the Art and Next Questions
SOHO Highlights on Non-Bulky cHL: Can We Treat Early Disease With Sh…
Feat.
D. Straus
09:24
SOHO Highlights: State of the Art and Next Questions
ECHELON-1 Data on Brentuximab Vedotin for Frontline Advanced cHL: Ex…
Feat.
D. Straus
10:47
SOHO Highlights: State of the Art and Next Questions
Surveying the Induction and Maintenance Therapy Landscape in Newly D…
Feat.
S. Lonial
20:52
SOHO Highlights: State of the Art and Next Questions
MM State of the Art: Approaches to Smoldering, MRD as a Prognostic M…
Feat.
S. Lonial
29:37
SOHO Highlights: State of the Art and Next Questions
CML State of the Art: Dasatinib/Imatinib Dose Optimization, STAMPi A…
Feat.
M. Deininger
34:50
SOHO Highlights: State of the Art and Next Questions
MPNs State of the Art: What Is the Response to Ruxolitinib vs. BAT? …
Feat.
S. Verstovsek
27:43
SOHO Highlights: State of the Art and Next Questions
MDS State of the Art: Imetelstat/Roxadustat for Anemia, Oral HMAs, A…
Feat.
G. Garcia-Manero
11:39
SOHO Highlights: State of the Art and Next Questions
Early Stage cHL Management: Bulky vs. Non-bulky Disease, Better Chem…
Feat.
D. Straus
14:25
SOHO Highlights: State of the Art and Next Questions
SOHO Highlights on Untreated MCL: How Does Deferred Therapy Work? Wh…
Feat.
J. Cohen
19:43
SOHO Highlights: State of the Art and Next Questions
SOHO Highlights on R/R MCL: The Role of BTKis, CAR-T, and Chemothera…
Feat.
J. Cohen
20:07
SOHO Highlights: State of the Art and Next Questions
R/R PTCL State of the Art: Allo-SCT vs. Auto-SCT? Can Pralatrexate C…
Feat.
K. Savage
18:07
SOHO Highlights: State of the Art and Next Questions
SOHO Updates on 1L MZL: Can RT Help in Early Stage MALToma? Is R-Ben…
Feat.
R. Marcus
34:46
SOHO Highlights: State of the Art and Next Questions
DLBCL State of the Art: Does Gene Expression Help With the Disease? …
Feat.
S. Dave
24:38
SOHO Highlights: State of the Art and Next Questions
Dana-Farber CLL State of the Art: A Review of BTK Inhibitors Data in…
Feat.
J. Brown
24:52
SOHO Highlights: State of the Art and Next Questions
CAR-T State of the Art: What Therapies Will Be Available in the Next…
Feat.
S. Giralt
29:51
SOHO Highlights: State of the Art and Next Questions
AML State of the Art: Older Patients Management, MRD, Total Oral Com…
Feat.
A. Zeidan
29:28
SOHO Highlights: State of the Art and Next Questions
ALL State of the Art at MD Anderson: Hyper-CVAD Combinations, MiniHC…
Feat.
H. Kantarjian